Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Total Liabilities : ¥748 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Chengdu Easton Biopharmaceuticals Co Total Liabilities?

Chengdu Easton Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥748 Mil.

Chengdu Easton Biopharmaceuticals Co's quarterly Total Liabilities increased from Sep. 2023 (¥644.31 Mil) to Dec. 2023 (¥743.33 Mil) and increased from Dec. 2023 (¥743.33 Mil) to Mar. 2024 (¥748.26 Mil).

Chengdu Easton Biopharmaceuticals Co's annual Total Liabilities increased from Dec. 2021 (¥483.60 Mil) to Dec. 2022 (¥573.08 Mil) and increased from Dec. 2022 (¥573.08 Mil) to Dec. 2023 (¥743.33 Mil).

Chengdu Easton Biopharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Easton Biopharmaceuticals Co Total Liabilities Chart

Chengdu Easton Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

289.64

435.61

483.60

573.08

743.33

Chengdu Easton Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															592.97	575.83	644.31	743.33	748.26

Chengdu Easton Biopharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Chengdu Easton Biopharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	661.094	+	(39.6	+	42.64
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	743

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3346.754	-	2603.42
	=	743

Chengdu Easton Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	666.672	+	(39.635	+	41.954
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	748

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3374.371	-	2626.11
	=	748

Chengdu Easton Biopharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Chengdu Easton Biopharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Easton Biopharmaceuticals Co Ltd (SHSE:688513) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731

Website

http://www.eastonpharma.cn

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Headlines

No Headlines